Figure 4 from Decoding the Genomic and Functional Landscape of Emerging Subtypes in Ovarian Cancer
Year: 2025
Type: other
Abstract: Clinical relevance of the subtypes. A, Distribution of patients across molecular subtypes stratified by treatment strategy: primary debulking surgery (PDS) and NACT. Unstable patients are those whose samples fall into multiple clusters. B, Kaplan–Meier survival analysis of platinum-free interval (PFI) across the subtypes (P < 0.0001). Unstable patients have been excluded. Patients in BRCA1-like and BRCA2-like subtypes show improved response to chemotherapy. C, Kaplan–Meier survival analysis of OS across molecular subtypes (P < 0.0001). Exclusion criteria like in B. BRCA2-like HRD cluster shows the most favorable prognosis. D, Cox proportional hazards model assessing the association between subtypes and PFI. BRCA1-like HRD was used as the reference category. The EMT HRP cluster was significantly associated with worse outcomes. The overall model was significant (log-rank p = 2e−5) with a concordance index of 0.635, indicating good discriminative ability. E, Primary chemotherapy response across molecular subtypes. The width of each bar is proportional to the number of patients in the respective subtype, reflecting the sample size distribution across groups. Poor responders are predominantly found in the HRP subtypes, with the EMT HRP subtype having the highest proportion. F, Kaplan–Meier survival analysis of 5 years OS comparing HR status determined by ovaHRDscar and molecular clustering (P < 0.0001). Cluster-defined HRD patients include stable patients within BRCA1-like and BRCA2-like subtypes. Molecular clustering identifies a subgroup of HRP scar patients in which 65% survived beyond 3 years after diagnosis (purple), compared with only 32% survival among patients classified as HRP by both methods (light blue).
Language: English
Subfield: Reproductive Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4415786958